GSK Reaches Another Settlement in Zantac Litigation
Provided by
Dow Jones
By Helena Smolak
GSK reached a settlement with plaintiff Isaac Dixon, resolving a case related to its discontinued heartburn medicine Zantac allegedly causing prostate cancer, filed in Illinois State court.
The British pharma giant said Wednesday that it will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.
GSK said it doesn't admit any liability in this settlement and will dismiss the case.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
September 11, 2024 13:00 ET (17:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
United States